6
http://www.who.int/mediacentre/news/releases/2007/pr61/en/index.html
7
Chan J.C., et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology.
8
http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx (National Diabetes Fact Sheet 2007).
9
10
Lakka H.M., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
11
Ort A., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study.
12
Key T., Reeves G.K., Spencer E.A. Symposium 1: Overnutrition: consequences and solutions for obesity and cancer risk.
13
Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.
14
Pan A., et al. Bidirectional association between depression and type 2 diabetes mellitus in women.
15
Emerging Risk Factors Collaboration et al. Diabetes mellitus, fasting glucose, and risk of causespecific death.
16
Huang E.S., Basu A., O’Grady M., Capretta J.C. Projecting the future: diabetes population size and related costs for the U.S.
17
Seligman H.K., Schillinger D. Hunger and socioeconomic disparities in chronic disease.
18
Yach D., Hawkes C., Gould C.L., Hofman K.J. The global burden of chronic diseases: overcoming impediments to prevention and control.
19
Ibid.
20
Glibenklamid, pochodna sulfonylomocznika II generacji, w Polsce dostępny jako lek Euclamin (przyp. tłum.).
21
Lipitor, lek zawierający atorwastatynę, w Polsce dostępny w postaci kilkunastu preparatów o innych nazwach, m.in. Atoris, Atovasterol, Tulip (przyp. tłum.).
22
ACCORD (Action to Control Cardiovascular Risk in Diabetes) „Akcja na rzecz kontroli ryzyka sercowo-naczyniowego w cukrzycy”, amerykański program badawczy ukierunkowany na wyszukanie najlepszych sposobów obniżenia wysokiego wskaźnika zawałów mięśnia sercowego i udarów mózgu u chorych na cukrzycę typu 2 (przyp. tłum.).
23
Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein H.C., et al. Effects of intensive glucose lowering in type 2 diabetes.
24
Chen L., et al. Reduction in consumption of sugar-sweetened beverages is associated with weight loss: the PREMIER trial.
25
Bhashyam S., et al. Aging is associared with myocardial insulin resistance and mitochondrial dysfunction.
26
Ryan A.S. Insulin resistance with aging: effects of diet and exercise.
27
Gaziano J.M., et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction.
28
Avandia w roku 2010 została wycofana z rynku europejskiego z powodu zaostrzonego ryzyka wystąpienia problemów kardiologicznych (przyp. tłum.).
29
McCarthy M.I. Genomics, type 2 diabetes, and obesity.
30
Przemoc strukturalna polega na przemocy wywieranej przez niesprawiedliwe struktury społeczne (przyp. tłum.).
31
Rappaport S.M. Implications of the exposome for exposure science.
32
Lichtenstein P., et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland.
33
Olshansky S.J., et al. A potential decline in life expectancy in the United States in the 21st century.
34
Bibbins-Domingo K., et al. Adolescent overweight and future adult coronary heart disease.
35
Diabetes Prevention Program Research Group, Knowler W.C., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.
36
Lim E.L., et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol.
37
Henry B., Kalynovskyi S. Reversing diabetes and obesity naturally: a NEWSTART lifestyle program.
38
Jessani S., et al. Should oral glucose tolerance testing be mandatory following acute myocardial infarction?
39
Khaw K.T., et al. Association of hemoglobin A1c with cardiovascular disease acute mortality in adults: the European prospective investigation into cancer in Norfolk.
40
Yaffe K., et al. The metabolic syndrome, inflammation, and risk of cognitive decline.
41
MCI, termin ang.,
42
de la Monte S.M., Wands J.R. Alzheimer’s disease is type 3 diabetes – evidence reviewed.
43
Stein J.L., Jack C.R. Jr, Weiner M.W., Toga A.W., Thompson P.M.; Cardiovascular Health Study; ADNI. Obesity is linked with lower brain volume in 700 AD and MCI patients.
44
45
Haffner S.M., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
46
The NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events.